Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
Date:3/8/2011

NEW YORK, March 8, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2010.

At December 31, 2010, the Company had cash, cash equivalents, interest receivable, and investment securities of $28.5 million, as compared to $35.9 million at December 31, 2009.  

The net loss for the fourth quarter ended December 31, 2010 was $5.3 million, or $0.09 per share, compared to a net loss of $4.7 million, or $0.08 per share, for the comparable quarter in 2009, representing an increase in net loss of $0.6 million.  Other research and development expenses increased by $2.6 million, as compared to the fourth quarter of 2009, principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs.  The fourth quarter of 2009 included a $1.5 million one-time research and development expense related to a terminated early-stage pipeline product candidate, which accounts for the net increase in other research and development expenses of $1.1 million as compared to the fourth quarter of 2009.

The net loss for the year ended December 31, 2010, was $20.3 million, or $0.34 per diluted share, compared to net income of $10.5 million, or $0.21 per diluted share, for the year ended December 31, 2009.  The change in net (loss) income was primarily attributable to a $21.6 million decrease in license revenue and a $3.6 million decrease in other revenue.  License revenue in the year ended December 31, 2009 was related to an amendment to the September 2007 sublicense agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. (JT/Torii) which eliminated the C
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
2. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
3. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
5. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
6. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
7. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
8. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
9. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
11. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015 Nortek Security & ... NTK ) and a leader in the residential ... announced it acquired mobile personal emergency response system ... Numera, Inc. Headquartered in ... implemented, mobile PERS products and cloud-based software platforms ...
(Date:6/30/2015)... 2015   Millar, Inc. , a leader in ... 2016 retirement of Craig Thummel , President/CEO and ... of service to the Company. The Company also announced ... of the Executive Management team as his successors. The ... currently Director of Sales and Marketing, as President, and ...
(Date:6/30/2015)... , June 24, 2015 ... announced the addition of the "Global Array ... The global array instruments market to ... the period 2014-2019 The global array instruments ... microarrays, protein microarrays, and others including tissue microarrays ...
Breaking Medicine Technology:Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 2Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 3Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 4Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2
... Jan. 27, 2011 /PRNewswire-Asia/ -- China Sky One ... Company") (Nasdaq: CSKI ), a leading ... of China ("PRC"), today announced that Heilongjiang Tianlong ... subsidiary, was named a "Top Ten Branded Company ...
... Cetero Research, the leading early-stage contract research organization ... industry milestone with the completion of its 20,000th ... as the unmatched leader in early-phase clinical development ... therapeutic expertise that Cetero offers to pharmaceutical, biotechnology ...
Cached Medicine Technology:China Sky One Medical Receives Medical Industry Awards 2China Sky One Medical Receives Medical Industry Awards 3Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study 2
(Date:6/30/2015)... FL (PRWEB) , ... June 30, 2015 , ... ... Jacksonville, reported today it has more than doubled the size of its medical ... The center’s medical staff -- which includes physicians, nurse practitioners and physician assistants ...
(Date:6/30/2015)... Plains, NJ (PRWEB) , ... June 30, 2015 , ... ... Techniques, they will be wowed with the incredible care that they receive and the ... care for their patients; but now they are proud to offer the same experience, ...
(Date:6/30/2015)... ... June 30, 2015 , ... The U.S. Women's National Soccer Team will face the ... match will be on Sunday, August 16th at Heinz Field in Pittsburgh at 1:30 p.m. ... at Finley Stadium in Chattanooga, TN. , The USA WNT previously played at Heinz Field ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... oncology centers are partnering to improve access to cancer prevention, screening and care ... Center (LCC) have announced an affiliation that will see Roswell Park faculty providing ...
(Date:6/30/2015)... ... June 30, 2015 , ... After more than five years of ... Administration, GlobalSun (TM) — sunscreen specifically formulated for the unique skin of all people ... hits the market just in time to help protect the skin of all people ...
Breaking Medicine News(10 mins):Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 3Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 4Health News:USA vs. Costa Rica Tickets at Heinz Field in Pittsburgh and Finley Stadium in Chattanooga: Ticket Down Slashes Presale Ticket Prices for Costa Rica vs. USA WNT 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 4Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 5Health News:GlobalSun – The First Sunscreen Developed for All People of Color – Hits The Market 2
... (TRE) is common in idiopathic autism. Early age at ... associated with a higher frequency of resistance to antiepileptic ... , a journal published by Wiley-Blackwell on behalf of ... to the Centers for Disease Control and Prevention (CDC), ...
... News) -- Hospitals are using a pricey blood-clotting drug in ... in which blood does not clot normally -- even though ... new research. Stanford University researchers found that use of ... times from use in 125 cases in 2000 to 17,813 ...
... , MONDAY, April 18 (HealthDay News) -- Infection with mononucleosis ... college students -- and little exposure to sunlight may combine ... new study suggests. "MS is more common at higher ... Dr. George C. Ebers, of the University of Oxford in ...
... Arbor, Mich., -- Childhood obesity affects 1 of every 6 ... lack of physical activity. Schools can play a key ... activeon the playground during recess and when they,re in gym. ... budget cuts, have prompted many schools to cut back on ...
... HealthDay Reporter , MONDAY, April 18 (HealthDay News) -- ... their own risks for common conditions are also likely to ... more a parent believes they,re going to get good news, ... said senior study author Colleen McBride, chief of the social ...
... drug overdose deaths in Vancouver,s Downtown Eastside dropped by ... America,s first supervised injection facility, according a new study ... the British Columbia Centre for Excellence in HIV/AIDS. ... is the first to assess the impact of supervised ...
Cached Medicine News:Health News:Treatment-resistant epilepsy common in idiopathic autism 2Health News:Off-Label Use of Clotting Drug Soars, Report Finds 2Health News:Can Common Virus, Lack of Sunlight Boost MS Risk? 2Health News:U-M experts: Gym gone but not forgotten? Parents want more physical activity at school for kids 2Health News:Parents Want Genetic Testing for Kids: Study 2Health News:Parents Want Genetic Testing for Kids: Study 3Health News:Overdose deaths down 35 percent after opening of Vancouver's supervised injection site: UBC-BC-CfE study 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: